Research studies seek
participants with memory loss, Alzheimer’s disease
Send a link to a friend
[November 02, 2018]
Alzheimer’s disease could affect more than 14 million Americans by 2050
if a cure isn’t found, the Alzheimer’s Association reports.
|
The Center for Alzheimer’s Disease and Related Disorders, part of
SIU Medicine’s Neuroscience Institute, is hoping new research
studies might change that.
Three clinical trials, including the Aware Study by AbbVie, Tauriel
Study by Genentech, and GRADUATE I Study by Roche, are now
recruiting participants with memory impairment or probable
mild-to-moderate Alzheimer’s disease. The goal of these studies is
test how well the medical treatments work at slowing the progression
of the disease and whether they are safe. All study-related drugs
and assessments will be provided at no cost to the participant.
Participants may also receive a stipend to cover travel, meals and
other related expenses.
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/directory_buttons.png)
[to top of second column] |
![](http://archives.lincolndailynews.com/2018/Nov/02/images/ads/current/maskeauction_sda_022614.png)
To qualify, participants must:
-
Be
between 50-90 years of age
-
Have
symptoms consistent with mild cognitive impairment or probable
Alzheimer’s disease
-
Be
willing to undergo position emission tomography (PET) scans and
magnetic resonance imaging (MRI)
-
Have
a reliable study partner or caregiver who is willing to
participate, attend study visits and answer questions about the
participant’s health
To learn more about these studies and qualifications, call Barbara
Lokaitis at 217-545-9737.
[SIU Medicine] |